MNPR vs PHAT: stock comparison and AI forecast
Monopar Therapeutics (MNPR) and Phathom Pharmaceuticals, Inc. (PHAT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
MNPR Monopar Therapeutics
- Market Cap
- $483M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
PHAT Phathom Pharmaceuticals, Inc.
- Market Cap
- $479M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- MNPR and PHAT have similar market capitalizations ($483M and $479M).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | MNPR | PHAT |
|---|---|---|
| Market Cap | $483M | $479M |
| P/B Ratio | 3.69x | – |
| EPS | – | $-0.42 |
| Book Value/Share | $19.50 | – |
| Revenue/Share | $0.00 | $3.40 |
| FCF/Share | – | $-0.26 |
Profitability & Margins
| Metric | MNPR | PHAT |
|---|---|---|
| ROE | -13.6% | – |
| ROA | -13.2% | – |
| ROIC | -16.9% | -15.0% |
| Gross Margin | – | 80.7% |
| Operating Margin | – | -9.3% |
| EBT Margin | – | -31.6% |
Financial Health
| Metric | MNPR | PHAT |
|---|---|---|
| Current Ratio | 33.56x | 1.76x |
| Quick Ratio | – | 1.72x |
| D/E Ratio | 0.03x | – |
| Financial Leverage | 1.03x | – |
| Interest Coverage | -24.4x | -0.0x |
| Working Capital | $131M | $133M |
Cash Flow
| Metric | MNPR | PHAT |
|---|---|---|
| Operating Cash Flow | -$12M | -$21M |
| Free Cash Flow | – | -$21M |
| Capital Spending | – | -$300K |
| FCF/Sales | – | -7.7% |
| CapEx/Sales | – | 0.1% |
Operational Efficiency
| Metric | MNPR | PHAT |
|---|---|---|
| Asset Turnover | 0.00x | 0.80x |
| Receivables Turnover | – | 2.5x |
| Inventory Turnover | – | 7.0x |
| Fixed Assets Turnover | – | 294.0x |
| Days Sales Outstanding | – | 143 days |
| Days Inventory | – | 52 days |
| Payables Period | – | 76 days |
| Cash Conversion Cycle | – | 119 days |
Income Statement
| Metric | MNPR | PHAT |
|---|---|---|
| Total Revenue | $0.00M | $275M |
| Operating Income | -$22M | -$25M |
| Net Income | -$18M | – |
| R&D Expense | $15M | $32M |
| SG&A Expense | – | $215M |
| Cost of Goods Sold | – | $53M |
Dividend & Shareholder Information
| Metric | MNPR | PHAT |
|---|---|---|
| Shares Outstanding | 7M | 81M |
MNPR vs PHAT: stock comparison and AI forecast
Which is bigger, MNPR or PHAT?
MNPR and PHAT have similar market capitalizations ($483M and $479M).
Which one does Intratio's AI model rank higher, MNPR or PHAT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.